Acadia Pharmaceuticals to Announce Third Quarter 2020 Financial Results on November 4, 2020
October 21 2020 - 4:05PM
Business Wire
Acadia to Host Conference Call and Webcast on
Wednesday, November 4, 2020, at 4:30 p.m. Eastern Time
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that
it will report third quarter financial results on Wednesday,
November 4, 2020, after the close of the U.S. financial markets.
Acadia’s management team will also host a conference call and
webcast on Wednesday, November 4, 2020, at 4:30 p.m. Eastern Time
to discuss financial results and operations.
The conference call may be accessed by dialing 855-638-4820 for
participants in the United States or Canada and 443-877-4067 for
international callers (reference passcode 6266016). A telephone
replay of the conference call may be accessed through November 18,
2020 by dialing 855-859-2056 for callers in the United States or
Canada and 404-537-3406 for international callers (reference
passcode 6266016). The conference call also will be webcast live on
Acadia’s website, www.acadia-pharm.com, under the investors section
and will be archived there until December 2, 2020.
About Acadia Pharmaceuticals
Acadia is trailblazing breakthroughs in neuroscience to elevate
life through science. For more than 25 years we have been working
at the forefront of healthcare to bring vital solutions to people
who need them most. We developed and commercialize the first and
only approved therapy for hallucinations and delusions associated
with Parkinson’s disease psychosis. Our late-stage development
efforts are focused on dementia-related psychosis, negative
symptoms of schizophrenia and Rett syndrome, and in early-stage
clinical research we are exploring novel approaches to pain
management, and cognition and neuropsychiatric symptoms in central
nervous system disorders. For more information, visit us at
www.acadia-pharm.com and follow us on LinkedIn.
Forward-Looking Statements
Statements in this press release that are not strictly
historical in nature are forward-looking statements. These
statements include but are not limited to statements regarding the
timing of future events. These statements are only predictions
based on current information and expectations and involve a number
of risks and uncertainties. Actual events or results may differ
materially from those projected in any of such statements due to
various factors, including the risks and uncertainties inherent in
drug development, approval and commercialization. For a discussion
of these and other factors, please refer to Acadia’s annual report
on Form 10-K for the year ended December 31, 2019 as well as
Acadia’s subsequent filings with the Securities and Exchange
Commission. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof.
This caution is made under the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. All
forward-looking statements are qualified in their entirety by this
cautionary statement and Acadia undertakes no obligation to revise
or update this press release to reflect events or circumstances
after the date hereof, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201021005909/en/
Media Contact: Acadia Pharmaceuticals Inc. Eric Endicott (858)
914-7161 media@acadia-pharm.com
Investor Contact: Acadia Pharmaceuticals Inc. Mark Johnson, CFA
(858) 261-2771 ir@acadia-pharm.com
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Sep 2023 to Sep 2024